Improved design of prodromal Alzheimer's disease trials through cohort enrichment and surrogate endpoints

Journal of Alzheimer's Disease

Volumn 36, Issue 3, 2013, Pages 475-486

  Macklin, Eric A ^a,b   Blacker, Deborah ^a,b,c   Hyman, Bradley T ^a,b   Betensky, Rebecca A ^a,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Alzheimer's disease; clinical trials as topic; National Alzheimer's Coordinating Center Uniform Data Set; surrogate endpoint; survival analysis

Indexed keywords

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL DEMENTIA RATING; COHORT ANALYSIS; COMMUNITY LIVING; DISEASE COURSE; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; PREDICTION; PRIORITY JOURNAL; RISK FACTOR;

EID: 84881473829     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-122212     Document Type: Article

References (40)

1. Jack CR Jr, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, Thies B, Phelps CH (2011) Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 257-262
2. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9, 119-128
3. American Psychiatric Association (2007) Practice guideline for the treatment of patients with Alzheimer's disease and other dementias, American Psychiatric Association Arlington, V.A.
4. Holmes C, Boche D,Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA (2008) Long-term effects of Abeta42 immunisation in Alzheimer's disease: Follow-up of a randomised, placebocontrolled phase I trial. Lancet 372, 216-223
5. Blennow K (2010) Biomarkers in Alzheimer's disease drug development. Nat Med 16, 1218-1222
6. Emery VO (2011) Alzheimer disease: Are we intervening too late? Pro. J Neural Transm 118, 1361-1378
7. Feldman HH, Jacova C (2007) Primary prevention and delay of onset of AD/dementia. Can J Neurol Sci 34(Suppl 1), S84-S89
8. Sano M, Grossman H, Van Dyk K (2008) Preventing Alzheimer's disease : Separating fact from fiction. CNS Drugs 22, 887-902
9. Plassman BL, Langa KM, McCammon RJ, Fisher GG, Potter GG, Burke JR, Steffens DC, Foster NL, Giordani B, Unverzagt FW, Welsh-Bohmer KA, Heeringa SG, Weir DR, Wallace RB (2011) Incidence of dementia and cognitive impairment, not dementia in the United States. Ann Neurol 70, 418-426
10. Vandenberghe R, Van Laere K, Ivanoiu A, Salmon E, Bastin C, Triau E, Hasselbalch S, Law I, Andersen A, Korner A, Minthon L, Garraux G, Nelissen N, Bormans G, Buckley C, Owenius R, Thurfjell L, Farrar G, Brooks DJ (2010) 18Fflutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial. Ann Neurol 68, 319-329
11. Food and Drug Administration (2013) Guidance for industry: Alzheimer's disease: Developing drugs for the treatment of early stage disease, http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/ UCM338287.pdf, Accessed 23 February 2013
12. Schneider LS (2010) The potential and limits for clinical trials for early Alzheimer's disease and some recommendations. J Nutr Health Aging 14, 295-298
13. Daly E, Zaitchik D, Copeland M, Schmahmann J, Gunther J, Albert M (2000) Predicting conversion to Alzheimer disease using standardized clinical information. Arch Neurol 57, 675-680
14. Albert MS, Moss MB, Tanzi R, Jones K (2001) Preclinical prediction of AD using neuropsychological tests. J Int Neuropsychol Soc 7, 631-639
15. Albert M, Blacker D, Moss MB, Tanzi R, McArdle JJ (2007) Longitudinal change in cognitive performance among individuals with mild cognitive impairment. Neuropsychology 21, 158-169
16. Blacker D, Lee H, Muzikansky A, Martin EC, Tanzi R, McArdle JJ, Moss M, Albert M (2007) Neuropsychological measures in normal individuals that predict subsequent cognitive decline. Arch Neurol 64, 862-871
17. Dickerson BC, Sperling RA, Hyman BT, Albert MS, Blacker D (2007) Clinical prediction of Alzheimer disease dementia across the spectrum of mild cognitive impairment. Arch Gen Psychiatry 64, 1443-1450
18. Morris JC, Weintraub S, Chui HC, Cummings J, Decarli C, Ferris S, Foster NL, GalaskoD, Graff-Radford N, Peskind ER, Beekly D, Ramos EM, KukullWA (2006) The Uniform Data Set (UDS): Clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord 20, 210-216
19. Beekly DL, Ramos EM, Lee WW, Deitrich WD, Jacka ME, Wu J, Hubbard JL, Koepsell TD, Morris JC, Kukull WA (2007) The National Alzheimer's Coordinating Center (NACC) database: The Uniform Data Set. Alzheimer Dis Assoc Disord 21, 249-258
20. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL (1982) A new clinical scale for the staging of dementia. Br J Psychiatry 140, 566-572
21. Morris JC (1993) The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 43, 2412-2414
22. Delis D, Kramer J, Kaplan E, Ober B. (1987) The California Verbal Learning Test. The Psychological Corporation, New York, N.Y.
23. Grober E, Buschke H (1987) Genuine memory deficits in dementia. Dev Neuropsychol 3, 13-36
24. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198
25. Reitan RM (1958) Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills 8, 271-276
26. Wechsler D (1988) The Wechsler Adult Intelligence Scale-Revised. The Psychological Corporation, New York, N.Y.
27. Benton A, Hamsher K (1976) Multilingual Aphasia Examination. University of Iowa Press, Iowa City, I.A.
28. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944
29. Wechsler D (1997) Wechsler Memory Scale-Third Edition. The Psychological Corporation, San Antonio, T.X.
30. Hothorn T, Hornik K, Zeileis A (2006) Unbiased recursive partitioning: A conditional inference framework. J Comput Graph Stat 15, 651-674
31. Strobl C, Boulesteix AL, Kneib T, Augustin T, Zeileis A (2008) Conditional variable importance for random forests. BMC Bioinformatic 9, 307
32. Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA (1982) Evaluating the yield of medical tests. JAMA 247, 2543-2546
33. Uno H, Cai T, Pencina MJ, D'Agostino RB, Wei LJ On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Stat Med 30, 1105-1117
34. Lakatos E (1988) Sample sizes based on the log-rank statistic in complex clinical trials. Biometrics 44, 229-241
35. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368, 387-403
36. Coley N, Andrieu S, Jaros M,Weiner M, Cedarbaum J, Vellas B (2011) Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer's disease trials. Alzheimers Dement 7, 602-610 e602
37. Fleming TR, DeMets DL (1996) Surrogate end points in clinical trials: Are we being misled? Ann Intern Med 125, 605-613
38. Freidlin B, Korn EL (2010) Biomarker-Adaptive clinical trial designs. Pharmacogenomics 11, 1679-1682
39. Cook T, DeMets DL (2010) Review of draft FDA adaptive design guidance. J Biopharm Stat 20, 1132-1142
40. Renfro LA, Carlin BP, Sargent DJ (2012) Bayesian adaptive trial design for a newly validated surrogate endpoint. Biometrics 68, 258-267